Tech Company Financing Transactions
OnKure Funding Round
Acorn Bioventures and Cormorant Asset Management invested in a $55 million Series B funding round for OnKure. The financing was announced on 3/5/2021.
Transaction Overview
Company Name
Announced On
3/5/2021
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series B
Investors
Acorn Bioventures (Lead Investor) (Isaac Manke)
Proceeds Purpose
Proceeds will be used to advance the Company's next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1105 Spruce St.
Boulder, CO 80302
USA
Boulder, CO 80302
USA
Phone
Website
Email Address
Overview
OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony Piscopio
Chief Financial Officer
Michael Carruthers
Chief Medical Officer
Gail Eckhardt
Chief Operating Officer
John DeMattei
Chief Scientific Officer
Xuedong Liu
Vice President
James Winkler
VP - General Counsel
Keith Olivia
Browse more venture capital transactions:
Prev: 3/5/2021: Postscript venture capital transaction
Next: 3/5/2021: Ecomedes venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs